Clinical Trial Update: To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence trial comparing a 4 mg prototype mini nicotine lozenge to Nicorette in healthy smokers completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• 4 mg prototype mini nicotine lozenge (nicotine lozenge)
• NICORETTE (Nicotine polacrilex)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tobacco Use Disorder | Phase 1 | Status: COMPLETED | Results posted: 2019-12-04